{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:41:36Z","timestamp":1792237296231,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007083","name":"Orion Research Fundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Hospital District of Helsinki and Uusimaa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","award":["190434"],"award-info":[{"award-number":["190434"]}],"id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","award":["210469"],"award-info":[{"award-number":["210469"]}],"id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["325667"],"award-info":[{"award-number":["325667"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["278123"],"award-info":[{"award-number":["278123"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejps.2024.106735","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T17:19:18Z","timestamp":1709054358000},"page":"106735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes \u2013 detailed studies on CYP3A inhibitors"],"prefix":"10.1016","volume":"198","author":[{"given":"Helin\u00e4","family":"Kahma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Paludetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kurkela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Filppula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-2788","authenticated-orcid":false,"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106735_bib0001","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s002280000211","article-title":"Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers","volume":"56","author":"Addison","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2024.106735_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cpt.2907","article-title":"Intestinal metabolism of diclofenac by polymorphic UGT2B17 correlates with its highly variable pharmacokinetics and safety across populations","volume":"114","author":"Ahire","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0003","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1211\/jpp.59.10.0008","article-title":"Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport","volume":"59","author":"Amioka","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106735_bib0004","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2024.106735_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0006","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.healun.2005.05.002","article-title":"The effect of \u03b2-blocker use on cyclosporine level in cardiac transplant recipients","volume":"24","author":"Bader","year":"2005","journal-title":"J. Heart Lung Transplant"},{"key":"10.1016\/j.ejps.2024.106735_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/1389200023337315","article-title":"Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions","volume":"3","author":"Boelsterli","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2024.106735_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0091270004269870","article-title":"Pharmacokinetics of aripiprazole and concomitant lithium and valproate","volume":"45","author":"Citrome","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106735_bib0009","first-page":"1143","article-title":"Disposition and chemical stability of telmisartan 1-O-acylglucuronide","volume":"27","author":"Ebner","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0010","unstructured":"EMA (2012) Guideline on the investigation of drug interactions. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf [accessed 1 February 2023]."},{"key":"10.1016\/j.ejps.2024.106735_bib0011","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0012","unstructured":"FDA (2020) In vitro drug interaction studies \u2014 Cytochrome P450 enzyme- and transporter-mediated drug interactions; guidance for industry. https:\/\/www.fda.gov\/media\/134582\/download [accessed 1 February 2023]."},{"key":"10.1016\/j.ejps.2024.106735_bib0013","unstructured":"FDA (2014) Striverdi respimat clinical pharmacology biopharmaceutics review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/203108Orig1s000TOC.cfm [accessed 11 January 2023]."},{"key":"10.1016\/j.ejps.2024.106735_bib0014","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition","volume":"34","author":"Galetin","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2174\/138920008786049276","article-title":"Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations","volume":"9","author":"Gertz","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2024.106735_bib0016","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40262-022-01204-4","article-title":"Can mechanistic static models for drug-drug interactions support regulatory filing for study waivers and label recommendations?","volume":"62","author":"Gomez-Mantilla","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106735_bib0017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-9236(03)00118-8","article-title":"Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice","volume":"74","author":"Greenblatt","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0018","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1124\/dmd.114.059147","article-title":"Assessment of intestinal availability (FG) of substrate drugs of cytochrome P450s by analyzing changes in pharmacokinetic properties caused by drug\u2013drug interactions","volume":"42","author":"Hisaka","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0019","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1253\/circj.70.1269","article-title":"Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention","volume":"70","author":"Hong","year":"2006","journal-title":"Circ. J."},{"key":"10.1016\/j.ejps.2024.106735_bib0020","first-page":"387","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2024.106735_bib0021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dmpk.2016.11.002","article-title":"Toxicological potential of acyl glucuronides and its assessment","volume":"32","author":"Iwamura","year":"2017","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106735_bib0022","first-page":"849","article-title":"Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals","volume":"22","author":"Jurima-Romet","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105810","article-title":"An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity","volume":"162","author":"Kahma","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106735_bib0024","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1399-0012.1997.tb01046.x","article-title":"Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients","volume":"11","author":"Kaijser","year":"1997","journal-title":"Clin. Transplant"},{"key":"10.1016\/j.ejps.2024.106735_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.2003.tb01356.x","article-title":"Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil","volume":"94","author":"Kakumoto","year":"2003","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejps.2024.106735_bib0026","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138920007780866807","article-title":"Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions","volume":"8","author":"Kalgutkar","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2024.106735_bib0027","first-page":"763","article-title":"Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 In vitro","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0028","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106735_bib0029","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.102.038992","article-title":"Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide","volume":"303","author":"Kumar","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0009-9236(99)90048-6","article-title":"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin","volume":"66","author":"Lilja","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0031","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1021\/acs.jmedchem.7b00510","article-title":"Glucuronides as potential anionic substrates of human cytochrome P450 2C8 (CYP2C8)","volume":"60","author":"Ma","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2024.106735_bib0032","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/bdd.1857","article-title":"Time-dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor","volume":"34","author":"Masubuchi","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0033","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1124\/dmd.30.10.1143","article-title":"Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine","volume":"30","author":"Masubuchi","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0034","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(92)90098-E","article-title":"Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients","volume":"11","author":"McKee","year":"1992","journal-title":"Epilepsy Res."},{"issue":"Suppl 6","key":"10.1016\/j.ejps.2024.106735_bib0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2165\/00003495-198800366-00015","article-title":"Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study","volume":"36","author":"McPhillips","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2024.106735_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir","volume":"63","author":"Menon","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejps.2024.106735_bib0037","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13318-017-0417-y","article-title":"The role of drug metabolites in the inhibition of cytochrome P450 enzymes","volume":"42","author":"Mikov","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106735_bib0038","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/j.1552-4604.1993.tb01926.x","article-title":"Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration","volume":"33","author":"Mueller","year":"1993","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106735_bib0039","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00125-003-1034-7","article-title":"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide","volume":"46","author":"Niemi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejps.2024.106735_bib0041","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"Obach","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0042","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0043","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2133\/dmpk.25.16","article-title":"System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes","volume":"25","author":"Parkinson","year":"2010","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106735_bib0044","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0009-2797(00)00198-8","article-title":"Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions","volume":"129","author":"Ritter","year":"2000","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejps.2024.106735_bib0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u201cIn silico\u201d simulations to assess the \u201cin vivo\u201d consequences of \u201cin vitro\u201d metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejps.2024.106735_bib0046","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/dmd.115.066985","article-title":"Contribution of major metabolites toward complex drug-drug interactions of deleobuvir: in vitro predictions and in vivo outcomes","volume":"44","author":"Sane","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0047","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/875512250301900303","article-title":"Rhabdomyolysis due to combined therapy with cerivastatin and diclofenac","volume":"19","author":"Schechner","year":"2003","journal-title":"J. Pharm. Technol."},{"key":"10.1016\/j.ejps.2024.106735_bib0048","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0076-6879(95)49038-8","article-title":"Mechanism-based enzyme inactivators","author":"Silverman","year":"1995"},{"key":"10.1016\/j.ejps.2024.106735_bib0049","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cpt.2259","article-title":"Do inhibitory metabolites impact DDI risk assessment? Analysis of in vitro and in vivo data from NDA reviews between 2013 and 2018","volume":"110","author":"Steinbronn","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/psp4.12110","article-title":"Quantitative prediction of drug-drug interactions involving inhibitory metabolites in drug development: how can physiologically based pharmacokinetic modeling help?","volume":"5","author":"Templeton","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106735_bib0051","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/mol.56.1.226","article-title":"Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide","volume":"56","author":"Terrier","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106735_bib0052","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions","volume":"96","author":"Tornio","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0053","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0054","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1124\/dmd.121.000497","article-title":"Static and dynamic projections of drug-drug interactions caused by cytochrome P450 3A time-dependent inhibitors measured in human liver microsomes and hepatocytes","volume":"49","author":"Tseng","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89","volume":"32","author":"Valentin","year":"2002","journal-title":"Ann. ICRP"},{"key":"10.1016\/j.ejps.2024.106735_bib0056","first-page":"66","article-title":"The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition","volume":"13","author":"VandenBrink","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.ejps.2024.106735_bib0057","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.110.032177","article-title":"Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106735_bib0058","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4254\/wjh.v9.i5.270","article-title":"Addition of simvastatin to carvedilol non responders: a new pharmacological therapy for treatment of portal hypertension","volume":"9","author":"Wani","year":"2017","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejps.2024.106735_bib0059","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hup.869","article-title":"Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder","volume":"22","author":"Winter","year":"2007","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.ejps.2024.106735_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajhg.2008.08.004","article-title":"Adaptive evolution of UGT2B17 copy-number variation","volume":"83","author":"Xue","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejps.2024.106735_bib0061","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2024.106735_bib0062","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2024.106735_bib0063","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/clpt.2010.252","article-title":"Are circulating metabolites important in drug-drug interactions?: quantitative analysis of risk prediction and inhibitory potency","volume":"89","author":"Yeung","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106735_bib0064","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/dmd.115.066944","article-title":"Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro","volume":"44","author":"Zhang","year":"2016","journal-title":"Drug Metab. Dispos."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:59:44Z","timestamp":1731459584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":64,"alternative-id":["S0928098724000460"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106735","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes \u2013 detailed studies on CYP3A inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106735"}}